GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Junshi Biosciences Co Ltd (HKSE:01877) » Definitions » Days Sales Outstanding

Shanghai Junshi Biosciences Co (HKSE:01877) Days Sales Outstanding : 116.83 (As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Shanghai Junshi Biosciences Co Days Sales Outstanding?

Shanghai Junshi Biosciences Co's average Accounts Receivable for the three months ended in Mar. 2024 was HK$529.6 Mil. Shanghai Junshi Biosciences Co's Revenue for the three months ended in Mar. 2024 was HK$413.7 Mil. Hence, Shanghai Junshi Biosciences Co's Days Sales Outstanding for the three months ended in Mar. 2024 was 116.83.

The historical rank and industry rank for Shanghai Junshi Biosciences Co's Days Sales Outstanding or its related term are showing as below:

HKSE:01877' s Days Sales Outstanding Range Over the Past 10 Years
Min: 49.91   Med: 88.77   Max: 1300.15
Current: 1300.15

During the past 8 years, Shanghai Junshi Biosciences Co's highest Days Sales Outstanding was 1300.15. The lowest was 49.91. And the median was 88.77.

HKSE:01877's Days Sales Outstanding is ranked worse than
96.3% of 893 companies
in the Biotechnology industry
Industry Median: 72.43 vs HKSE:01877: 1300.15

Shanghai Junshi Biosciences Co's Days Sales Outstanding increased from Mar. 2023 (81.60) to Mar. 2024 (116.83).


Shanghai Junshi Biosciences Co Days Sales Outstanding Historical Data

The historical data trend for Shanghai Junshi Biosciences Co's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Junshi Biosciences Co Days Sales Outstanding Chart

Shanghai Junshi Biosciences Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Days Sales Outstanding
Get a 7-Day Free Trial 74.13 92.81 87.74 207.23 87.13

Shanghai Junshi Biosciences Co Quarterly Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Days Sales Outstanding Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 81.60 106.61 - - 116.83

Competitive Comparison of Shanghai Junshi Biosciences Co's Days Sales Outstanding

For the Biotechnology subindustry, Shanghai Junshi Biosciences Co's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Junshi Biosciences Co's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Junshi Biosciences Co's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Shanghai Junshi Biosciences Co's Days Sales Outstanding falls into.



Shanghai Junshi Biosciences Co Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Shanghai Junshi Biosciences Co's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

Days Sales Outstanding (A: Dec. 2023 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2022 ) + Accounts Receivable (A: Dec. 2023 )) / count ) / Revenue (A: Dec. 2023 )*Days in Period
=( (259.887 + 524.711) / 2 ) / 1643.457*365
=392.299 / 1643.457*365
=87.13

Shanghai Junshi Biosciences Co's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

Days Sales Outstanding (Q: Mar. 2024 )
=Average Accounts Receivable /Revenue*Days in Period
=( (Accounts Receivable (A: Dec. 2023 ) + Accounts Receivable (A: Mar. 2024 )) / count ) / Revenue (A: Mar. 2024 )*Days in Period
=( (524.711 + 534.547) / 2 ) / 413.668*365 / 4
=529.629 / 413.668*365 / 4
=116.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai Junshi Biosciences Co  (HKSE:01877) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.


Shanghai Junshi Biosciences Co Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Shanghai Junshi Biosciences Co's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Junshi Biosciences Co (HKSE:01877) Business Description

Traded in Other Exchanges
Address
Nos. 36 and 58, Hai Qu Road, Room 1003, Level 10, Building 2, Pilot Free Trade Zone, Shanghai, CHN
Shanghai Junshi is a China-based biotechnology company that was founded in 2012 and listed on the Hong Kong Stock Exchange and STAR board of the Shanghai Stock Exchange in 2018 and 2020, respectively. It received approval for its first core asset at the end of 2018, a PD-1 inhibitor called Tuoyi, or toripalimab. It also successfully created etesevimab, one of the earliest neutralizing antibodies for COVID-19 treatment, which was out-licensed to Eli Lilly and obtained U.S. Food and Drug Administration approval in February 2021. It also has an adalimumab biosimilar approved in 2022 and is working on an oral COVID-19 treatment, VV116.

Shanghai Junshi Biosciences Co (HKSE:01877) Headlines

No Headlines